Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19

Widysanto, Allen; Kurniawan, Andree; Lugito, Nata Pratama Hardjo; Yuniarti, Mira; Gunawan, C.; Angela, Angela; Wiryanto, Jessica; Levinna,; Pradhana, Tasya

doi:10.1016/j.cyto.2020.155393

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The government has implemented a number of policies to combat the spread of the virus, including the designation of the Covid-19 virus outbreak as a national disaster by Presidential Decree of the Republic of Indonesia number 2 of 2020 concerning Stipulation of Non-Natural Disasters the Spread of Corona Virus Disease 2019 . The government has implemented Large-Scale Social Restrictions (PSBB) for areas included in the red zone by Minister of Health Regulation (Permenkes) Number 9 of 2020 concerning PSBB Guidelines (Widysanto et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Social Assistance Programs During the COVID-19 Pandemic: Helping or Giving Addiction to the Public

Haimah

Nurphanudin²,

Setyowati

et al. 2022

IJD

View full text Add to dashboard Cite

The emergence of a pandemic caused a lot of difficulties faced by the community to survive. This caused the government to intervene and provide various assistance to the community. However, there are often problems in the process of providing this assistance. This study aims to evaluate social assistance provided by the government to the community. This research will be conducted utilizing a qualitative methodology. This study utilized secondary data acquired from still-relevant research or previous investigations. This study found that there was the use of incomplete data and confusing regulations, so social assistance was abused. Some people have jobs and decide to register on the pre-employment card. Then some people are economically capable but do not report themselves so that later they can still get social assistance from the government again.Keywords: Social Assistance, Abuse, Community, Government. AbstrakMunculnya pandemi menyebabkan banyak kesulitan yang dihadapi masyarakat untuk bertahan hidup. Hal ini menyebabkan pemerintah turun tangan dan memberikan berbagai bantuan kepada masyarakat. Namun, seringkali ada kendala dalam proses pemberian bantuan ini. Penelitian ini bertujuan untuk mengevaluasi bantuan sosial yang diberikan oleh pemerintah kepada masyarakat. Penelitian ini akan dilakukan dengan menggunakan metodologi kualitatif. Penelitian ini menggunakan data sekunder yang diperoleh dari penelitian yang masih relevan atau penyelidikan sebelumnya. Penelitian ini menemukan adanya penggunaan data yang tidak lengkap dan peraturan yang membingungkan sehingga bansos disalahgunakan. Beberapa orang memiliki pekerjaan dan memutuskan untuk mendaftar di kartu prakerja. Kemudian sebagian masyarakat yang mampu secara ekonomi tetapi tidak melapor agar nantinya masih bisa mendapatkan bantuan sosial dari pemerintah lagi.Kata kunci: Bansos, Penyalahgunaan, Masyarakat, Pemerintah.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of Social Assistance Programs During the COVID-19 Pandemic: Helping or Giving Addiction to the Public

Haimah

Nurphanudin²,

Setyowati

et al. 2022

IJD

View full text Add to dashboard Cite

show abstract

Beneficial and harmful outcomes of tocilizumab in severe COVID‐19: A systematic review and meta‐analysis

et al. 2021

View full text Add to dashboard Cite

Introduction:The results of studies of tocilizumab (TCZ) in COVID-19 are contradictory. Our study aims to update medical evidence from controlled observational studies and randomized clinical trials (RCTs) on the use of TCZ in hospitalized patients with COVID-19. Methods:We searched the following databases from January 1, 2020 to April 13, 2021 (date of the last search): MEDLINE database through the PubMed search engine and Scopus, using the terms ("COVID-19" [Supplementary Concept]) AND "tocilizumab" [Supplementary Concept]).Results: Sixty four studies were included in the present study: 54 were controlled observational studies (50 retrospective and 4 prospective) and 10 were RCTs. The overall results provided data from 20,616 hospitalized patients with COVID-19: 7668 patients received TCZ in addition to standard of care (SOC) (including 1915 patients admitted to intensive care units (ICU) with reported mortality) and 12,948 patients only receiving SOC (including 4410 patients admitted to the ICU with reported mortality). After applying the random-effects model, the hospital-wide (including ICU) pooled mortality odds ratio (OR) of patients with COVID-19 treated with TCZ was 0.73 (95% confidence interval (CI) = 0.56-0.93). The pooled hospital-wide mortality OR was 1.25 (95% CI = 0.74-2.18) in patients admitted at conventional wards versus 0.66 (95% CI = 0.59-0.76) in patients admitted to the ICU. The pooled OR of hospitalwide mortality (including ICU) of COVID-19 patients treated with TCZ plus corticosteroids (CS) was 0.67 (95% CI = 0.54-0.84). The pooled in-hospital mortality OR was 0.71 (95% CI = 0.35-1.42) when TCZ was early administered (≤10 days from symptom onset) versus 0.83 (95% CI 0.48-1.45) for late administration (>10 days from symptom onset). The meta-analysis did not find significantly higher risk for secondary infections in COVID-19 patients treated with TCZ.Conclusions: TCZ prevented mortality in patients hospitalized for COVID-19. This benefit was seen to a greater extent in patients receiving concomitant CS and when TCZ administration occurred within the first 10 days after symptom onset.

show abstract

Effects of the COVID-19 pandemic on cardiovascular disease financing in Indonesia (JKN claims data analysis 2019–2020)

Nugraheni¹,

Retnaningsih²,

Mubasyiroh³

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

The disease burden related to non-communicable diseases is a major public health problem in Indonesia. About one-third of all deaths in Indonesia are caused by cardiovascular disease. This study describes the cost of cardiovascular disease from claims data for Advanced Referral Health Facilities at BPJS Kesehatan before and during the COVID-19 pandemic. We analyzed claims data on the National Health Insurance system managed by BPJS. The data comes from referral health facilities throughout Indonesia in 2019 and 2020. Cardiovascular service claims data by sex and age group were analyzed descriptively and with different tests between years. There was a decrease in the number of patients accessing cardiovascular services at referral health facilities for all genders, age groups, and types of main diagnoses, by around 27.8%, from 933,017 (2019) to 673,801 (2020). There was a significant decrease in total claims for all types of cardiovascular disease during the COVID-19 pandemic compared to before, especially the reduction in aneurysms and aortic dissection (40.2%) and hypertensive heart disease (39.6%). The decline also occurred in all sexes and age groups, with an average percentage decline of 31.2%. Our findings show that the reduction in the cost of cardiovascular disease claims goes hand in hand with the decrease in the number of cardiovascular patient visits. To guarantee treatment for cardiovascular disease patients during the COVID-19 pandemic, BPJS can maximize the telemedicine services that have been built. The organizer of the National Health Insurance program in Indonesia has developed a JKN mobile application that has the potential for telemedicine services guaranteed by JKN. On the other hand, BPJS needs to limit promotive and preventive budgets related to CVD so that it does not become a potential catastrophic financing.

show abstract

Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19

Cited by 3 publications

References 26 publications

Evaluation of Social Assistance Programs During the COVID-19 Pandemic: Helping or Giving Addiction to the Public

Evaluation of Social Assistance Programs During the COVID-19 Pandemic: Helping or Giving Addiction to the Public

Beneficial and harmful outcomes of tocilizumab in severe COVID‐19: A systematic review and meta‐analysis

Effects of the COVID-19 pandemic on cardiovascular disease financing in Indonesia (JKN claims data analysis 2019–2020)

Contact Info

Product

Resources

About